Drug Profile
Arimoclomol - Zevra Therapeutics
Alternative Names: Arimoclomol citrate; BRX-345; MIPLYFFA; OR-01; OR-04Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Biorex
- Developer Food and Drug Administration; LadRx Corporation; Orphazyme; University of Kansas Medical Center
- Class Anti-inflammatories; Antineoplastics; Antiparkinsonians; Chlorinated hydrocarbons; Hydroxylamines; Oxides; Piperidines; Pyridines; Small molecules
- Mechanism of Action Heat shock transcription factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Niemann-Pick disease type C
- Phase II Gaucher's disease
- No development reported Glioblastoma; Parkinson's disease
- Discontinued Amyotrophic lateral sclerosis; Inclusion body myositis
Most Recent Events
- 28 Mar 2024 Zevra Therapeutics announces intention to submit regulatory applications in EU and other parts of the world
- 28 Mar 2024 Zevra Therapeutics plans to launch Arimoclomol for Niemann-Pick disease type C in USA
- 28 Mar 2024 No recent reports of development identified for preclinical development in Parkinson's-disease in Denmark (PO)